MIRABEGRON | APGDI | ||
25MG,50MG | |||
Yes | No | ||
2030-Mar-28 | 2017-Jun-28 | ||
None | None | ||
None | No | ||
MYRBETRIQ is a beta-3 adrenergic agonist indicated for the treatment of: ? Overactive bladder (OAB) in adult patients with symptoms of urge urinary incontinence, urgency, and urinary frequency, either alone or in combination with the muscarinic antagonist solifenacin succinate. ? Neurogenic detrusor overactivity (NDO) in pediatric patients aged 3 years and older and weighing 35 kg or more. |
4 | 2 | 2 |
Total Other Developers | 24 |
---|
Drugs with Suitability | No |
---|
25MG | ** | ** | Up | - | 2 |
50MG | ** | ** | Up | - | 2 |
NDA Sales Available | Total Generic Sales Available |
---|---|
Yes | 2 |
ANDA No | Generic Co | Manufacturer Name | Operations | Manufacturer Address | Country |
---|---|---|---|---|---|
****** | ***** *** | ***** ******* | *********** | ****-*, **** **. ***, ***, ****** - **, ******* ******** ****, *****, ******, *********** ******, ***** (***) | *** |
****** | ***** ****** | ***** ************ ******* | *********** | **** **. *-*/*&* *******, (******* ******** ****) ******, ******* ***** *.*. **. **, ***-******, ****-*********, *********, ******* ******, ***** (***) | *** |
Download GenUS Drug Report
Research Delta Advisor, G4,Sani Apartment, Bank of india lane, Ellora park, Vadodara 390023
+91 94997 68112
nimish@researchdelta.com